Healthcare Sector

Apollo Hospitals Enterprise Ltd shares touched a new 52-week high of ₹8,330 after the company reported robust Q4 FY26 results, supported by strong profit growth, higher hospital occupancy, improved operating margins, and positive healthcare demand trends. Investor sentiment also strengthened following the Cloudnine deal, merger approval, and dividend announcement.

Indian benchmark indices ended marginally lower on May 21, 2026, with Nifty closing near 23,654 and Sensex slipping 135 points amid concerns over RBI rate hikes, weak manufacturing PMI, rising crude oil prices, rupee weakness, and renewed FII selling. Defence and Realty stocks supported the market, while IT, FMCG, and Media remained under pressure.

Biocon is undergoing a strategic transformation with succession planning, appointing Claire Mazumdar as a likely successor, while strengthening biosimilars, restructuring operations, and advancing innovation-led biotech growth.

Healthcare funds can be defensive, while growing at a rapid pace during selective phases of its life cycle

According to reports, the USFDA made various observations concerning Sun Pharma. First, the company did not take appropriate safeguards to avoid API contamination.

According to a business announcement, net profit increased by 79% to ₹909 Crore in the fourth quarter of FY24, from ₹506 Crore in the same period in FY23.

The total net profit for the fiscal year ended March 31, 2024 was ₹1,656 Crore, up from ₹1,245 Crore the previous year, according to the business.

The net profit and EBITDA margin excluding ex-Cenexi, a contract manufacturing firm that Gland acquired for more than ₹1,000 Crore last year.

This approval builds on company’s successful track record of bringing the first interchangeable insulin, Semglee.

Lupin said the business is thoroughly reviewing the findings and would respond to the USFDA within the timeframe specified.